Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19

BACKGROUND: Neutralizing monoclonal antibodies (MAbs) are a promising therapy for early coronavirus disease 2019 (COVID-19), but their effectiveness has not been confirmed in a real-world setting. METHODS: In this quasi-experimental pre-/postimplementation study, we estimated the effectiveness of MA...

Descripción completa

Detalles Bibliográficos
Autores principales: Webb, Brandon J, Buckel, Whitney, Vento, Todd, Butler, Allison M, Grisel, Nancy, Brown, Samuel M, Peltan, Ithan D, Spivak, Emily S, Shah, Mark, Sakata, Theadora, Wallin, Anthony, Stenehjem, Eddie, Poulsen, Greg, Bledsoe, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314951/
https://www.ncbi.nlm.nih.gov/pubmed/34327256
http://dx.doi.org/10.1093/ofid/ofab331

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8314951/
https://www.ncbi.nlm.nih.gov/pubmed/34327256
http://dx.doi.org/10.1093/ofid/ofab331

Ejemplares similares